News - NLSDays - NLSDays

Latest news in cooperation with Nordic Life Science

Mia Phillipson – Pioneering immunotherapies

23 April 2024 | 4:52 am

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur. “Most of all, I am a scientist. Yes, absolutely. This is my main occupation and the one in which I have the most expertise,” says Mia Phillipson, who […]

Nykode initiates Phase 2 trial in second line HPV16-positive cervical cancer

22 April 2024 | 8:19 am

The company has announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq) in patients with HPV16positive, PD-L1-positive, recurrent, or metastatic cervical cancer. “Initiating the VB10.16 trial for HPV16-positive cervical cancer […]

BioArctic and Eisai sign research evaluation agreement

22 April 2024 | 8:08 am

The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. “I […]

Building and bridging the most innovative life science cluster in the EU

17 April 2024 | 1:06 pm

Boston’s Kendall Square, close to Massachusetts Institute of Technology (MIT), is known as “The most innovative square mile on the planet” and, apart from our preference for the metric system, there just might be something we could learn from the Americans. One of the recommendations is that public and private stakeholders, inspired by the success […]

Ultimovacs implements operational adjustments, including reducing its workforce

17 April 2024 | 8:36 am

Ultimovacs has announced a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several cancer indications and immunotherapy combinations, and we are prepared for both challenges and accomplishments along the way. We anticipate […]

Sound Bioventures announces investment in Theolytics

17 April 2024 | 8:30 am

Sound Bioventures participated in the financing round, which raised a total of USD 24.5 million, and joins an existing investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford. In conjunction with this financing, Thomas Tan, Principal at Sound Bioventures, will join Theolytics’ Board of Directors. Read more: […]

Exclusive interview: Thomas Eldered predicts 2024

17 April 2024 | 4:47 am

Personalized medicine, weight loss remedies and new treatments for widespread ailments are among the rising areas of high interest in the biotechnology and therapeutic arenas, according to executive chairman of Flerie Invest, Thomas Eldered. Thomas Eldered talked with Nordic Life Science about the Nordic and global life science financial landscapes and Flerie’s role in funding […]

The causes of the KI freezer failure according to internal report

16 April 2024 | 7:13 am

On 12 April, the internal investigation into the freezer failure during the Christmas holidays in 2023 was presented in the Neo building at Karolinska Institutet. The investigation has been led by KI’s head of security and it points to clear technical as well as organizational shortcomings. Taken together, a chain of these shortcomings caused the […]

Mölnlycke acquires wound cleansing manufacturer

15 April 2024 | 3:00 pm

Mölnlycke Health Care has signed an agreement to acquire P.G.F. Industry Solutions, the Austrian manufacturer of Granudacyn, a range of solutions for wound cleansing and moisturizing. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing, […]

Curida secures equity investment and appoints new CEO

15 April 2024 | 4:10 am

Curida Holding has announced a significant growth investment from Signet Healthcare Partners, a New York-based healthcare private equity firm together with existing shareholders, Canica, Investinor, Klaveness Marine and Farvatn Private Equity. This investment will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position, it states. The total investment […]

Latest news in cooperation with Nordic Life Science

Mia Phillipson – Pioneering immunotherapies

Nykode initiates Phase 2 trial in second line HPV16-positive cervical cancer

BioArctic and Eisai sign research evaluation agreement

Building and bridging the most innovative life science cluster in the EU

Ultimovacs implements operational adjustments, including reducing its workforce

Sound Bioventures announces investment in Theolytics

Exclusive interview: Thomas Eldered predicts 2024

The causes of the KI freezer failure according to internal report

Mölnlycke acquires wound cleansing manufacturer

Curida secures equity investment and appoints new CEO

Join the conference!

Join the conference!

© 2024 SwedenBIO. All Rights Reserved
Legal Notices

Latest news in cooperation with Nordic Life Science

Join the conference!

© 2024 SwedenBIO. All Rights ReservedLegal Notices

© 2024 SwedenBIO. All Rights Reserved
Legal Notices